Description |
cyclin A2 |
S-phase kinase associated protein 2 |
Image |
|
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
- 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
- 6-O-Cyclohexylmethyl Guanine
- [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
- 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
- 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
- N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
- 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
- O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
- (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
- N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
- 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
- 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
- N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
- 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
- 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
- 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
- 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
- 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
- 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
- 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
- (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
- 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
- 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
- (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
- 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
- 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
- Variolin B
|
|
Diseases |
|
|
GWAS |
|
|
Interacting Genes |
49 interacting genes:
ARID4A
BRCA1
BRCA2
BTG1
BUB1B
CALM1
CDC20
CDC25C
CDC6
CDK1
CDK2
CDK3
CDKN1A
CDKN1B
CDT1
DRD2
DTNBP1
E2F1
E2F3
FANCC
FEN1
H1-1
H1-5
HERC5
HIRA
ITGB3BP
KAT2B
MAD2L1
MAGEA11
MYBL2
NFYA
PGR
POLA1
PRC1
PSMD4
PTMA
RAD23A
RB1
RBL1
RBL2
RPA1
SKP1
SKP2
SP1
TAF1
TP53
TRAF3IP1
UBTF
USP37
|
65 interacting genes:
AKT1
BRAP
BRCA1
BTG1
BTG2
CCNA2
CCNE1
CCNT1
CDC14B
CDC34
CDH1
CDK2
CDK9
CDKN1A
CDKN1B
CDKN1C
CDT1
CEBPA
CFLAR
CHKA
CKS1B
CKS1BP7
CUL1
CUL4A
DDB1
DUSP1
E2F1
ELF4
EP300
ESR1
FZR1
GPS1
KPNA1
KPNA6
MEF2D
MTOR
MYB
MYBL2
MYC
NLK
ORC1
PAX8
PDCD4
PFDN1
PIM1
POLR2A
PSMD9
RAG2
RB1
RBL2
RND3
SIRT4
SIRT6
SKP1
SLC9A3R1
SMAD4
SQSTM1
TAL1
TCF3
TRIM21
UBB
VHL
WEE1
YWHAB
YY1
|
Entrez ID |
890 |
6502 |
HPRD ID |
00453 |
03256 |
Ensembl ID |
ENSG00000145386
|
ENSG00000145604
|
Uniprot IDs |
P20248
|
A0A024R069
D6R9R7
Q13309
|
PDB IDs |
1E9H
1FIN
1FVV
1GY3
1H1P
1H1Q
1H1R
1H1S
1H24
1H25
1H26
1H27
1H28
1JST
1JSU
1OGU
1OI9
1OIU
1OIY
1OKV
1OKW
1OL1
1OL2
1P5E
1PKD
1QMZ
1URC
1VYW
2BKZ
2BPM
2C4G
2C5N
2C5O
2C5V
2C5X
2C6T
2CCH
2CCI
2CJM
2I40
2IW6
2IW8
2IW9
2UUE
2UZB
2UZD
2UZE
2UZL
2V22
2WEV
2WFY
2WHB
2WIH
2WIP
2WMA
2WMB
2WPA
2WXV
2X1N
3EID
3EJ1
3EOC
3F5X
4BCK
4BCM
4BCN
4BCP
4CFM
4CFN
4CFU
4CFV
4CFW
4CFX
4EOI
4EOJ
4EOK
4EOL
4EOM
4EON
4EOO
4EOP
4EOQ
4EOR
4EOS
4FX3
5CYI
5IF1
5LMK
5NEV
6ATH
6GVA
6P3W
6Q6G
6Q6H
6RIJ
6SG4
7B5L
7B5R
|
1FQV
1FS1
1FS2
1LDK
2ASS
2AST
7B5L
7B5M
7B5R
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|